产品详情 |
Edit |   |
Antigenic Specificity | C5b-9, Rat |
Clone | 2A1 |
Host Species | Mouse |
Reactive Species | rat |
Isotype | IgG1 |
Format | unconjugated |
Size | 100 µg |
Concentration | 100 µg/ml |
Applications | frozen sections, FC, immunoassay, IF, paraffin sections, WB |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | The monoclonal antibody 2A1 recognizes rat C5b-9. The antibody was shown to compete with antibodies to human C9 for its binding site on the C5b-9 complex, indicating that the reactive epitope is located on the C9 molecule. C5b-9 membrane attack complexes are assembled from five precursor molecules in the serum. Proteolytic cleavage of C5 by C5 convertase generates C5b which initiates assembly of the C5b-9 complex. The last step of C5b-9 complex formation involves polymerization of C9 which accompanies insertion of the complex into the cell membrane. During formation of C5b-8 and C9 polymerization, neoantigens are generated which are unique to the C5b-9 complex and are not present on any of the individual native complex components. The complement regulatory proteins CD59 and complement S-protein can both prevent C5b-9 insertion into the cell membrane. The formed SC5b-9 complex is unable to attach to cells and is cytolytically inactive.C5b-9 is involved in the progression of chronic proteinuric renal disease by mediating continuous tubulointerstitial damage. Early tubulointerstitial injury in the remnant kidney can be improved when C5b-9 complex forming is abrogated. The monoclonal antibody 2A1 was raised against a rat C5b-9 neoantigen. Monoclonal antibody 2A1 can be used as a coating antibody to detect C5b-9 in plasma and urine samples. |
Immunogen | Rat C5b-9 |
Other Names | Membrane attack complex, MAC, TCC, Terminal Complement Complex |
Gene, Accession # | n/a |
Catalog # | HM3033 |
Price | |
Order / More Info | C5b-9, Rat Antibody from HYCULT BIOTECH |
Product Specific References | n/a |
产品资料 |
|
|